Divisions of Pediatric Cardiology, The Pediatric Heart Institute, 23454Joe DiMaggio Children's Hospital, Hollywood, Florida, FL, USA.
Pediatric Cardiothoracic Surgery, The Pediatric Heart Institute, 23454Joe DiMaggio Children's Hospital, Hollywood, Florida, FL, USA.
World J Pediatr Congenit Heart Surg. 2021 Mar;12(2):213-219. doi: 10.1177/2150135120975763.
Surgical pulmonary artery banding (PAB) has been limited in practice because of later requirement for surgical removal or adjustment. The aim of this study is to describe our experience creating a dilatable PAB via transcatheter balloon dilation (TCBD) in congenital heart disease (CHD) patients.
Retrospective chart review of adjustable PAB-outline anatomical variants palliated and patient outcomes.
Sixteen patients underwent dilatable PAB-median age 52 days (range 4-215) and weight 3.12 kg (1.65-5.8). Seven (44%) of the patients were premature, 11 (69%) had ventricular septal defect(s) with pulmonary over-circulation, four (25%) atrioventricular septal defects, and four (25%) single ventricle physiology. Subsequent to the index procedure: five patients have undergone intracardiac complete repair, six patients remain well palliated with no additional intervention, and four single ventricles await their next palliation. One patient died from necrotizing enterocolitis (unrelated to PAB) and one patient required a pericardiocentesis postoperatively. Five patients underwent TCBD of the PAB without complication-Two had one TCBD, two had two TCBD, and another had three TCBD. The median change in saturation was 14% (complete range 6-22) and PAB diameter 1.7 mm (complete range 1.1-5.2). Median time from PAB to most recent outpatient follow-up was 868 days (interquartile range 190-1,079).
Our institution has standardized a PAB technique that allows for transcatheter incremental increases in pulmonary blood flow over time. This methodology has proven safe and effective enough to supplant other institutional techniques of limiting pulmonary blood flow in most patients-allowing for interval growth or even serving as the definitive palliation.
由于外科肺动脉带(PAB)后期需要手术切除或调整,因此在实践中受到限制。本研究旨在描述我们通过经导管球囊扩张(TCBD)在先天性心脏病(CHD)患者中创建可扩张 PAB 的经验。
回顾性分析可调节 PAB-外形解剖变异姑息治疗和患者结局的图表。
16 名患者接受了可扩张 PAB-中位年龄 52 天(范围 4-215),体重 3.12kg(1.65-5.8)。7 名(44%)患者为早产儿,11 名(69%)有室间隔缺损伴肺循环过度,4 名(25%)房室间隔缺损,4 名(25%)单心室生理学。在指数手术后:5 名患者接受了心脏内完全修复,6 名患者继续姑息治疗,无其他干预,4 名单心室等待下一次姑息治疗。1 名患者死于坏死性小肠结肠炎(与 PAB 无关),1 名患者术后需要心包穿刺术。5 名患者接受了 PAB 的 TCBD,无并发症-2 名患者进行了 1 次 TCBD,2 名患者进行了 2 次 TCBD,另 1 名患者进行了 3 次 TCBD。饱和度中位数变化为 14%(完全范围为 6-22),PAB 直径为 1.7mm(完全范围为 1.1-5.2)。从 PAB 到最近门诊随访的中位时间为 868 天(四分位间距 190-1079)。
我们机构已经标准化了一种 PAB 技术,该技术可随着时间的推移通过经导管逐渐增加肺血流量。这种方法已被证明是安全有效的,足以替代其他机构限制肺血流量的技术-允许间隔生长,甚至作为确定性姑息治疗。